viewOpen Orphan PLC

Venn Life picks up €2.8mln phase II trial contract

Venn's IRT department has also been approved by a top ten pharma major as a service provider

Picture of drugs on a production line
Vendor qualification is a significant milestone for the IRT division, said Venn

Venn Life Sciences Holdings plc (LON:VENN) has been awarded a new contract worth €2.8mln to carry out a phase II trial for a European biotech.

The trial is for an immunotherapeutic treatment for Multiple Sclerosis, involves patients in six countries across Europe and starts in October.

In addition, Venn's Interactive Response Technology (IRT) department, which selects patients for trials, has picked up a project in China from a top ten pharma major after being approved by the group as a service provider.

Venn hailed this deal, saying vendor qualification is a significant milestone for the IRT division and represents an exciting opportunity to grow a global account.

Tony Richardson, chief executive, added Venn was now benefiting from a good balance of repeat business, client referrals and new business wins.

“I am particularly pleased with our success in IRT. Coming through the vendor qualification and audit process with 'big-pharma' represents a significant step for our organisation and high quality execution of this initial project should result in a rich vein of new business."

A specialist contract research organisation (CRO), Venn Life provides an outsourcing service for drug development, clinical trial management and resourcing solutions.  

Quick facts: Open Orphan PLC

Price: 6.35 GBX

Market: AIM
Market Cap: £16.17 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within...

6 days, 14 hours ago


Holding(s) in Company

12 hours, 22 minutes ago

Holding(s) in Company

1 day, 10 hours ago

Euronext Growth Dublin Notice

1 day, 18 hours ago

Offer Wholly Unconditional

4 days, 19 hours ago

Schedule One Update

5 days, 12 hours ago

2 min read